Investment Management

Cowen Investment Management is the Investment Management division of Cowen. We aim to build on Cowen’s core insights by developing differentiated, actively managed strategies that seek to meet the dynamic needs of our clients

Cowen Investment Management delivers differentiated strategies to a diverse client base of sophisticated investors including institutions, corporations, pension plans, sovereign wealth funds, foundations and endowments, multi-family offices and high net worth individuals.

We seek to pursue strategies that are focused in areas in which Cowen has an existing knowledge base and aim to align with Cowen’s ESG mission. Directly and through its related advisors, we offer strategies in Healthcare and Life Sciences, Sustainable Investments, Healthcare Royalties, Merger Arbitrage, and Activism. 

Cowen Investment Management is a signatory to the UN Principles of Responsible Investment (UNPRI).

Investment management professionals and clients around a conference room table

Leading with Vision

Cowen Healthcare Investments (CHI)

Cowen Healthcare Investments (CHI) makes mid-to-late stage investments into innovative private biopharmaceutical and healthcare companies. Cowen began investing in this strategy in 2012. 

Meet Our CHI Team

Latest CHI News
News

Escient Pharmaceuticals Announces $120 Million Series C Financing

Read the article “Escient Pharmaceuticals Announces $120 Million Series C Financing”
News

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

Read the article “VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares”
News

Nested Therapeutics Launches With $125 Million Financing

Read the article “Nested Therapeutics Launches With $125 Million Financing”
News

ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases

Read the article “ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases”
News

Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals

Read the article “Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals”
News

Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests

Read the article “Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests”
News

Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson’s Disease

Read the article “Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson’s Disease”
News

2seventy bio Secures $170 Million in Private Placement Equity Financing

Read the article “2seventy bio Secures $170 Million in Private Placement Equity Financing”
CHI Portfolio
  • Nested Therapeutics logo
    Nested Therapeutics
  • Aktis Oncology logo
    Aktis Oncology
  • Delfi Diagnostics logo
    Delfi Diagnostics
  • Neuron23 logo
    Neuron23
  • 2seventy bio logo
    2seventy bio
  • Scipher Medicine logo
    Scipher Medicine
  • Electra Therapeutics logo
    Electra Therapeutics
  • Anaveon logo
    Anaveon
  • Acelyrin, Inc. logo
    Acelyrin, Inc.
  • Lycia Therapeutics logo
    Lycia Therapeutics
  • Obsidian Therapeutics logo
    Obsidian Therapeutics
  • Arch Oncology logo
    Arch Oncology
  • Omega Therapeutics logo
    Omega Therapeutics
  • Prometheus logo
    Prometheus
  • Neuron23™ logo
    Neuron23™
  • F2G logo
    F2G
  • Escient Pharmaceuticals logo
    Escient Pharmaceuticals
  • Freeline logo
    Freeline
  • Nodthera logo
    Nodthera
  • Autobahn logo
    Autobahn
  • Keros Therapeutics logo
    Keros Therapeutics
  • Larimar Therapeutics logo
    Larimar Therapeutics
  • Akouos logo
    Akouos
  • VectivBio logo
    VectivBio
  • AM Pharma logo
    AM Pharma
  • Cullinan Oncology logo
    Cullinan Oncology
  • Oncorus logo
    Oncorus
  • Repare Therapeutics logo
    Repare Therapeutics
  • Concentric Analgesics logo
    Concentric Analgesics
  • Inozyme Pharma logo
    Inozyme Pharma
  • KSQ logo
    KSQ
  • Evox Therapeutics logo
    Evox Therapeutics
  • Therachon logo
    Therachon*
  • Pliant Therapeutics logo
    Pliant Therapeutics
  • Cadent Therapeutics logo
    Cadent Therapeutics
  • Precision Biosciences logo
    Precision Biosciences
  • Semma Therapeutics logo
    Semma Therapeutics*
  • Orchard Therapeutics logo
    Orchard Therapeutics
  • Kezar Life Sciences logo
    Kezar Life Sciences
  • Compass Therapeutics logo
    Compass Therapeutics
  • Livongo logo
    Livongo
  • G1 Therapeutics logo
    G1 Therapeutics
  • True North Therapeutics logo
    True North Therapeutics*
  • Audentes logo
    Audentes
  • Corvus Pharmaceuticals logo
    Corvus Pharmaceuticals
  • Ovid Therapeutics logo
    Ovid Therapeutics
  • Editas Medicine logo
    Editas Medicine
  • Unum Therapeutics logo
    Unum Therapeutics*
  • MykoKardia logo
    MykoKardia
  • Aeglea Biotherapeutics logo
    Aeglea Biotherapeutics
  • KemPharma Inc logo
    KemPharma Inc
  • Global Blood Therapeutics logo
    Global Blood Therapeutics
  • American Well logo
    American Well
  • Naurex Inc logo
    Naurex Inc*
  • Blueprint Medicine logo
    Blueprint Medicine
  • Avalanche Biotech logo
    Avalanche Biotech*
  • Ultra Genyx Pharmaceuticals logo
    Ultra Genyx Pharmaceuticals
  • Bluebirdbio logo
    Bluebirdbio
  • GBT logo
    GBT

*CHI Portfolio Companies with an asterisk have been acquired and/or experienced a name change; the link provided is directed to each company’s current website.

Cowen Sustainable Investments (CSI)

Founded in 2018, Cowen Sustainable Investments (CSI) provides tailored financing and data analytics solutions to companies that are accelerating the world’s transition to an environmentally sustainable economy by addressing pollution, waste, and resource constraints. 

With a focus on companies of proven technologies and products that can be enhanced with data analytics resources as well as strong management teams, the investment themes pursued by CSI include clean transportation, sustainable food production, industrial efficiency as well as renewables and storage.

Meet Our CSI Team

Latest CSI News
News

Bevi Partners with Cowen Sustainable Investments on $70 Million Series D

Read the article “Bevi Partners with Cowen Sustainable Investments on $70 Million Series D”
News

quip Raises $100 Million in Funding to Redefine Oral Healthcare Globally

Read the article “quip Raises $100 Million in Funding to Redefine Oral Healthcare Globally”
News

ecoATM Gazelle Raises $75M of Growth Capital to Drive Global Smartphone Access and Sustainability

Read the article “ecoATM Gazelle Raises $75M of Growth Capital to Drive Global Smartphone Access and Sustainability”
News

Cowen Sustainable Investments Reaches Over $1.1 Billion in Platform Assets

Read the article “Cowen Sustainable Investments Reaches Over $1.1 Billion in Platform Assets”
News

Proterra Secures $200 Million Investment from Cowen Sustainable Advisors, Soros Fund Management, Generation Investment Management, and Broadscale Group

Read the article “Proterra Secures $200 Million Investment from Cowen Sustainable Advisors, Soros Fund Management, Generation Investment Management, and Broadscale Group”
News

ecoATM Announces Investment by Cowen Sustainable Advisors

Read the article “ecoATM Announces Investment by Cowen Sustainable Advisors”
CSI Portfolio
  • quip logo
    quip
  • ecoATM Gazelle logo
    ecoATM Gazelle
  • Proterra logo
    Proterra
  • ecoATM logo
    ecoATM
Ramius Advisors

Ramius is a focused and fundamentally research-driven merger arbitrage strategy.  The current Ramius merger arbitrage team has managed merger arbitrage strategies since 2011.

Meet Our Ramius Team

Starboard Value

Starboard Value is a New York-based investment adviser with a focused and fundamental approach to investing in publicly-traded US companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.

Starboard’s principals have managed investments in this manner since 2002. 

Learn more about Starboard Value.

HealthCare Royalty Partners (HCR)

Founded in 2006, HealthCare Royalty Partners (HCR) is an investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.

Learn more about HealthCare Royalty Partners.

Investment Management Team

Our team of dedicated investment professionals seek to capitalize on disruption and dislocation across market, geographies and sectors.

Investment management professional reviews report with a client
Start a Conversation
Get in touch with our Investment Management team to discuss Cowen’s Investment Management capabilities.